• In early April 2026, Twist Bioscience reported strong fiscal first‑quarter results and raised its full‑year 2026 revenue guidance, while also outlining a path toward adjusted EBITDA breakeven by year‑end.
• Despite this operational progress and continued institutional interest, some investors appear to be reassessing how much of the improved outlook is already embedded in expectations, leading to short‑term volatility.
• We’ll now examine how Twist Bioscience’s upgraded full‑year revenue guidance and breakeven ambitions influence the existing investment narrative and risks.

We've uncovered the 11 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Twist Bioscience Investment Narrative Recap

To own Twist Bioscience, you have to believe its DNA synthesis and NGS tools can keep gaining share, eventually supporting a sustainable move toward profitability. The upgraded 2026 revenue guidance and stated path to adjusted EBITDA breakeven keep that near term profitability milestone as the key catalyst, while the biggest ongoing risk remains the company’s unprofitable status and potential need for future capital. The recent share pullback on profit taking does not materially change these core drivers.

Among the recent updates, the raised full year 2026 revenue outlook to US$435 million to US$440 million stands out as most relevant. It reinforces the story that improving gross margins above 50 percent and expanding product adoption in NGS and SynBio could support the breakeven goal, even as short term volatility reminds you that expectations around that guidance and timeline can shift quickly.

Yet in contrast to the upbeat guidance, you should be aware that continued operating losses still leave open the risk of future dilution if...

Twist Bioscience's narrative projects $575.2 million revenue and $92.4 million earnings by 2028.

Uncover how Twist Bioscience's forecasts yield a $35.62 fair value, a 27% downside to its current price.

Exploring Other Perspectives

By contrast, the most pessimistic analysts were assuming roughly 15 percent annual revenue growth to about US$600.6 million by 2029, yet still no profits, highlighting how sharply views can differ and why it is worth weighing both the recent guidance upgrade and the risk of prolonged high costs before you decide which narrative feels closer to your own.

Explore 2 other fair value estimates on Twist Bioscience - why the stock might be worth as much as 19% more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Twist Bioscience research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Twist Bioscience research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Twist Bioscience's overall financial health at a glance.

Interested In Other Possibilities?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Outshine the giants: these 20 early-stage AI stocks could fund your retirement.
• Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.